4D Molecular Therapeutics

4DMT is a clinical-stage precision gene medicine company unlocking the full potential of gene therapy for rare and large market diseases such as lysosomal storage disorders, ophthalmology, neuromuscular diseases, and cystic fibrosis by harnessing the power of directed evolution. 4DMT's proprietary Therapeutic Vector Evolution platform enables a "disease-first" approach to product discovery and development, allowing for the customization of AAV vectors to target specific tissue types associated with underlying diseases. These proprietary and optimized AAV vectors are designed to provide targeted delivery through routine clinical routes, efficient transduction, reduced immunogenicity, and resistance to pre-existing antibodies—features that can help overcome known limitations of conventional AAV vectors in gene therapy development.